Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey
| Autor: | Süheyla Serin Senger, Gulgun Akkoclu, Melda Türken Ulusoy, Gürsel Ersan, Gulsun Akincioglu, Sukran Kose |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Hepatitis b e antigen
medicine.medical_specialty Tenofovir lcsh:QR1-502 Pharmaceutical Science Gastroenterology lcsh:Microbiology Serology Virological response Chronic hepatitis Internal medicine tenofovir disoproxil parasitic diseases medicine Pharmacology (medical) Liver injury medicine.diagnostic_test business.industry virus diseases Hepatitis B medicine.disease chronic Complementary and alternative medicine HBeAg Liver biopsy Immunology business medicine.drug |
| Zdroj: | Volume: 2, Issue: 03 87-92 Journal of Microbiology and Infectious Diseases Journal of Microbiology and Infectious Diseases, Vol 2, Iss 3, Pp 87-92 (2012) |
| ISSN: | 2146-9369 2146-3158 |
| DOI: | 10.5799/ahinjs.02.2012.03.0050 |
| Popis: | Objectives: The goal of therapy in chronic hepatitis B infection (CHB) is to impede liver injury by suppressing viral rep- lication. The study was aimed to determine the eficacy of tenofovir (TDF) in CHB infection for 48 weeks. Materials and methods: We retrospectively analyzed the data of 45 CHB patients treated by tenofovir. The patients were divided into two groups based on their hepatitis B e antigen status (HBeAg). Those who were eligible to therapy received TDF 300 mg once daily for 48 weeks. Serum alanine aminotransferase levels (ALT), hepatitis B virus DNA (HBV DNA), and viral serological markers were checked at three-month intervals. Liver biopsy scores were determined in all patients. Results: The mean age ± standard deviation (SD) was 35.8 ± 17.0 years, 26 (57.8 %) were male, and seven patients (15.5%) were treatment-experienced by a nucleos(t)ide analogue before TDF. HBeAg was positive in 17 (37.8%) patients. At week 48 among HBeAg positive (HBeAg +) patients\' biochemical and virological response rates at month-3, -6 and -12 were 64.7%, and 100%, 70.6%, and 94.1%, and 88.2%, and 64.7%, respectively. The serological response in HBeAg + patients was 29.4%. For HBeAg negative (HBeAg -) patients; biochemical, and virological response rates were 64.3%, and 96.4% at month 3; 82.1%, and 96.4% at month 6; and 100%, and 85.7% at month 12, respectively. At week 48 both groups had signiicant virological response (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|